DEA Moves to Tighten Grip on Another New Drug
Published Date: 5/26/2026
Proposed Rule
Summary
The DEA wants to put diphenidine, a drug, into Schedule I, which means it will be treated like the most tightly controlled substances. This change affects anyone who makes, sells, studies, or owns diphenidine, adding strict rules and penalties. You’ve got until June 25, 2026, to share your thoughts before the new rules might kick in.
Analyzed Economic Effects
4 provisions identified: 0 benefits, 4 costs, 0 mixed.
Diphenidine Placed in Schedule I
DEA proposes to place diphenidine (including its salts and isomers) in Schedule I of the Controlled Substances Act. If finalized, anyone who handles or proposes to handle diphenidine—manufacturers, distributors, importers, exporters, researchers, or possessors—will be subject to the full regulatory controls, and administrative, civil, and criminal sanctions that apply to Schedule I substances.
Unauthorized Possession and Penalties
Possession of diphenidine in any quantity in a manner not authorized by the CSA would be unlawful and could subject a person to prosecution under the CSA. Persons unwilling or unable to obtain DEA registration must surrender or transfer all quantities of diphenidine to a DEA-registered person before the effective date of any final scheduling action.
DEA Registration Required to Handle
If the rule is finalized, any person who handles diphenidine would need to be registered with DEA under 21 U.S.C. 822, 823, 957, and 958 and 21 CFR parts 1301 and 1312. Persons who currently handle diphenidine and are not registered may not continue to handle it unless DEA approves their registration; a person already registered to conduct research with another Schedule I substance may continue research on diphenidine only if they submit a completed application or modification not later than 90 calendar days after the date the final rule takes effect.
New Security, Recordkeeping, and Quota Rules
Registered handlers of diphenidine would need to meet Schedule I security requirements, labeling and packaging rules, quota-based manufacturing limits, inventory and biennial inventory requirements, specific records and reports (including automated reporting), and DEA order form and import/export rules as set out in 21 U.S.C. and 21 CFR parts cited in the proposal. Disposal of stocks must comply with 21 CFR part 1317 and other applicable laws.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-17531, Schedules of Controlled Substances: Temporary Placement of 5,6-Dichloro Brorphine, 5,6-Dichloro Desmethylchlorphine, N-Propionitrile Chlorphine, and Spirochlorphine in Schedule I of the Controlled Substances Act
The Drug Enforcement Administration (DEA) issues this temporary order to schedule 1-(1-(1-(4-bromophenyl)ethyl)piperidin-4- yl)-5,6-dichloro-1,3-dihydro-2H-benzo[d]imidazol-2-one (commonly known as 5,6-dichloro brorphine or SR-14968); 5,6-dichloro-1-(1-(4- chlorobenzyl)piperidin-4-yl)-1,3-dihydro-2H-benzo[d]imidazol-2-one (commonly known as 5,6-dichloro desmethylchlorphine or SR-17018); 3-(3- (1-(1-(4-chlorophenyl)ethyl)piperidin-4-yl)-2-oxo-2,3-dihydro-1H- benzo[d]imidazol-1-yl)propanenitrile (commonly known as N-propionitrile chlorphine or cychlorphine); and 8-(1-(4-chlorophenyl)ethyl)-1-phenyl- 1,3,8-triazaspiro[4.5]decan-4-one (commonly known as spirochlorphine or R-6890), including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers, and salts is possible, to schedule I under the Controlled Substances Act. DEA bases this action on a finding that placing 5,6-dichloro brorphine, 5,6-dichloro desmethylchlorphine, N- propionitrile chlorphine, and spirochlorphine in schedule I is necessary to avoid an imminent hazard to public safety. This order imposes the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis, or possess) or propose to handle these substances.
2026-17429, Schedules of Controlled Substances: Temporary Placement of Mitragynine Pseudoindoxyl, MGM-15, and MGM-16 in Schedule I
The Drug Enforcement Administration (DEA) is issuing this temporary order to schedule three 7-hydroxymitragynine-related substances (mitragynine pseudoindoxyl, MGM-15, and MGM-16), including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers, and salts is possible, in schedule I of the Controlled Substances Act. DEA bases this action on a finding that placing mitragynine pseudoindoxyl, MGM-15, and MGM-16 in schedule I is necessary to avoid an imminent hazard to public safety. This order imposes the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle these three 7-hydroxymitragynine-related substances.
2026-17385, Importer of Controlled Substances Application: Experic LLC
Experic LLC wants to become an official importer of some controlled substances, including certain drugs like tetrahydrocannabinols and nabilone. People and companies already registered can share their thoughts or ask for a hearing by September 25, 2026. This move could impact businesses dealing with these substances, so keep an eye on the deadline to have your say!
2026-17275, Catina Allen, N.P.; Decision and Order
Catina Allen, a nurse practitioner from Indiana, lost her DEA registration because she no longer has the legal right to handle controlled substances in her state. She didn’t ask for a hearing to challenge this, so the DEA officially revoked her registration, which expired on June 30, 2026. This means she can’t prescribe or manage controlled drugs anymore, affecting her medical practice and patients.
Previous / Next Documents
Previous: 2026-10379, Schedules of Controlled Substances; Removal of Exemption Status for Inactive Butalbital Products
The DEA wants to remove certain inactive butalbital prescription products from their special exemption list because these products aren’t available anymore or the companies behind them are gone. This means these products will now be treated like controlled substances, not exempt ones. If you have thoughts, you’ve got until June 25, 2026, to speak up—no money changes for active products, just a cleanup of the list!
Next: 2026-10381, Airworthiness Directives; Airbus SAS Airplanes
The FAA is updating safety rules for many Airbus A318, A319, A320, and A321 airplanes to fix a potential safety problem with certain parts. This update expands which parts are affected and applies to more planes, so operators need to check and possibly fix these parts soon. Comments on these changes are open until July 10, 2026, and following the new rules might cost some time and money but will keep flights safer.